Statement: the primary trial and the secondary trial do not record any of the same adverse events.
Primary_evidence: Adverse Events 1:   Total: 3/24 (12.50%)   Disseminated intravascular coagulation 0/24 (0.00%)   Death NOS 0/24 (0.00%)   Edema limbs 0/24 (0.00%)   Fatigue 0/24 (0.00%)   Hepatic failure 1/24 (4.17%)   Alanine aminotransferase increased 1/24 (4.17%)   Aspartate aminotransferase increased 1/24 (4.17%)   Blood bilirubin increased 0/24 (0.00%)   Ejection fraction decreased 1/24 (4.17%) Adverse Events 2:   Total: 9/22 (40.91%)   Disseminated intravascular coagulation 1/22 (4.55%)   Death NOS 1/22 (4.55%)   Edema limbs 1/22 (4.55%)   Fatigue 1/22 (4.55%)   Hepatic failure 0/22 (0.00%)   Alanine aminotransferase increased 0/22 (0.00%)   Aspartate aminotransferase increased 1/22 (4.55%)   Blood bilirubin increased 1/22 (4.55%)   Ejection fraction decreased 1/22 (4.55%)
Secondary_evidence: Adverse Events 1:   Total: 5/33 (15.15%)   Left Ventricular Thrombus * 1/33 (3.03%)   Nausea * 1/33 (3.03%)   Acute Cholecystitis * 1/33 (3.03%)   Renal Failure * 1/33 (3.03%)   Pneumonia * 1/33 (3.03%)